Background: Childhood mortality has decreased markedly over the last three decades. We undertook a study to determine trends in deaths from respiratory illness in children in England and Wales.
Introduction
Childhood mortality has decreased markedly in industrialised countries over the last three decades. [1] [2] [3] This fall has been attributed to many different improvements in healthcare including immunisations, advances in primary, secondary and neonatal care, and better understanding and treatment of childhood illnesses.
Respiratory infections and asthma are among the commonest of illnesses in childhood. They account for over a fifth of all general practitioner consultations and 15% of all hospital admissions for children in the United Kingdom. [4] [5] Most childhood respiratory illnesses are minor and self-limiting, but a minority of episodes of both acute and chronic respiratory disease are fatal. For example, in 1999 England and Wales, respiratory illness accounted for 9.6% of all deaths in 1-14 year olds and only injuries and poisonings (23.1%), malignancies (18.4%) and central nervous system diseases (13.0%) caused more deaths in that year. 3 All countries need accurate epidemiological information to prioritise, plan, implement and monitor public health interventions. 3, 6 There have been several studies of childhood deaths from individual respiratory illnesses such as asthma [7] [8] [9] and cystic fibrosis 10,11 but we are not aware of a detailed analysis of the trends in all the respiratory causes of deaths in children in England and Wales over a prolonged period. The aim of this study was to investigate these trends and to analyse the changing patterns of deaths from the individual diseases, which are responsible for most respiratory deaths in children, namely pneumonia, asthma, cystic fibrosis and bronchiolitis.
Methods
The data were provided by the Office for National Statistics (ONS). They consisted of all deaths registered from all causes in children aged between 28 days and 16 years in England and Wales from 1 January 1968 -31 December 2000. The data included the year of death, the cause of death under the International Classification of Disease (ICD), the age at death and gender. ICD eighth revision (ICD-8) codes were used from 1968-1978 and ICD ninth revision (ICD-9) codes from 1979-2000. We defined deaths from a respiratory cause as deaths recorded in ICD categories 460-519.9 combined with deaths due to cystic fibrosis (273.0 in ICD 8, 277.0-277.01 in ICD 9), pulmonary tuberculosis (011-012.9 and 019.0 in both ICD 8 and 9), whooping cough (pertussis) (033.0-033.9) and congenital anomalies of the respiratory system (748.0-748.9).
For analysis, we divided data into the age groups of post-neonatal infants (aged 28-364days), 1-5 years, 6-10 years and 11-16 years. Mortality rates were expressed per 100,000 population using the mid-year age-specific populations estimated by the ONS. We excluded neonatal deaths (deaths of infants aged less than 28 days) for two reasons. Firstly, the respiratory causes of deaths are very different in neonates.
1979-2000, as separate ICD coding for acute bronchiolitis was used from ICD-9.In ICD-8 acute bronchitis and bronchiolitis were coded together (466). We used Stata version 8 and SPSS version 11.0 for statistical analysis.
Results
The mortality rates from all causes for children aged [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Severe acute viral bronchiolitis is seen almost exclusively in infants aged between one month and one year. The mortality rate due to bronchiolitis in post-neonatal infants fell from 21.47 in 1979 to 1.82 in 2000 ( figure 6 ) and the absolute number of deaths fell from 137 to 11 per annum in the same period.
Mean (SD) male: female mortality rate ratios between 1968 and 2000 were 1.24 (0.17) for pneumonia, 1.41 (0.48) for asthma and 0.82 (0.28) for CF for children aged 28 days to 16 years and 1.77 (1.25) for bronchiolitis in post neonatal infants. There was no significant trend for male:female mortality rate ratios for pneumonia, asthma, CF or bronchiolitis during the study period.
Discussion
We have shown that, as in all industrialised countries, mortality rates in children have fallen dramatically in England and Wales in the last 32 years. The mortality rates due to respiratory illness have fallen more steeply than the overall rates, and a much smaller proportion of childhood deaths are now due to respiratory disease than in the past. The greatest improvements have been in infants and young children. Between 1968 and 2000, post-neonatal mortality rates from all causes decreased by 70%, while the rates due to respiratory deaths fell by 92% . In 1968, almost a half of deaths in post-neonatal infants were attributed to respiratory disease, but by 2000, this proportion had fallen to 13%. In 1-16 year olds, mortality rates for total deaths and respiratory deaths fell by 67% and 85% respectively between 1968 and 2000 and the percentage of deaths from respiratory disease fell from 17. There are some limitations to this study. A significant proportion of infants and children who die from pneumonia or bronchiolitis have a serious underlying condition, such as congenital anomalies of the cardiorespiratory system or CNS, a chromosomal abnormality or an immunodeficiency. The Office of National Statistics does not collect or provide data about these important co-existent conditions which significantly predispose children to death from a respiratory illness, We therefore cannot comment on their contribution to the trends we report. During the period we analysed, there were several changes in data collection by the ONS and its predecessors. Between 1984 and 1992 there were changes in the selection of the underlying cause of death from the death certificate. From 1993, automated coding was used to assign the cause of death. It has been suggested that changes in the mortality rates for pneumonia from 1993 may have been influenced by changes in data collection, but it is difficult to quantify these effects accurately.
12,13 However, our data do not show any sudden alteration in mortality from pneumonia in children at the time of these changes.
Changes in ICD coding can also affect mortality rates for asthma. 14 For example, in 1979, with the introduction of the ninth revision of the International Classification of Disease (ICD-9), deaths due to asthma with a mention of bronchitis were recorded under asthma unspecified (493.9) rather than bronchitis (490). This change in classification resulted in an apparent increase in the numbers of deaths from asthma, particularly in adults where there may be confusion with other diseases, such as chronic obstructive pulmonary disease. Stewart reported that the change from ICD-8 to ICD-9 coding caused an apparent 28% increase in asthma mortality in the total population 15 , although in younger age groups the effect was smaller. A survey of deaths from asthma in England showed death certification was more accurate in younger adults than in the elderly. 16 Sears showed that in New Zealand the accuracy of certification for asthma deaths was 100% in subjects under 35 years compared to only 50% in patients over 70 years. 17 However, there is little evidence to suggest that changes in diagnostic labelling by clinicians, or in ICD coding, explains the changes in the mortality rates from asthma for children we describe.
Because pneumonia, asthma, cystic fibrosis and bronchiolitis together accounted for most deaths due to respiratory illness between 28 days and 16 years in the period examined we examined these conditions in more detail.
Mortality rates due to childhood pneumonia have fallen in all age groups. The rates fell sharply between 1968 and the mid-1980s and have since levelled out. The fall was greatest in post-neonatal infants but even now most childhood deaths from pneumonia occur in the first year of life. In 2000, 40% of deaths due to pneumonia in children aged 28 days to 16 years occurred in post neonatal infants. Our data cannot explain why the number of deaths in children from pneumonia has fallen, but it is probable that improvements in primary, secondary and specialist care, in the use of antimicrobial agents, and in immunisations have all contributed to this reduction. For example, Mulholland has reported that HiB (Haemophilus influenzae B) conjugate vaccine, which was introduced into the United Kingdom in 1992, is 95% effective at preventing invasive HiB disease, 100% effective at preventing HiB Pneumonia and effective at preventing 21% of all radiologically defined pneumonia. 18 The high levels of protection against pertussis and measles, provided by immunisation are also likely to have affected mortality. It will be important to study the input of the proposed programme of pneumococcal vaccination in children on mortality from pneumonia in this population. These data could provide a valuable baseline to assess the impact of new public health clinical measures, which may be introduced to this country in the near future. For example, a universal immunisation programme against pneumococcal infection has been shown to be highly effective in preventing invasive pneumococcal disease, with a reduction in the incidence of radiologically confirmed pneumonia in children of about 25%. 19 We found that a decline in asthma mortality rates until the mid-1970s was followed by a rise in the 1980s, a further fall in the early 1990s and a levelling out since the mid-1990s. This pattern differs somewhat from that in other countries. In the United States, in children aged 0-17 years, asthma death rate increased by an average of 3.4 % per year from 1980 to 1998 8 . In Australia and Germany, asthma related deaths in childhood showed an increase between the mid -1970s and mid -1980s. 20 Campbell et al reported an irregular downward trend in 5-14 year olds from 1983 to1995 in England & Wales with an average fall of about 6% a year. 9 The survival of children and adults with cystic fibrosis has improved dramatically in the last 30 years. 21 In 1968, there were 118 deaths from cystic fibrosis in children, but by the year 2000 there were fifteen. The small increase in deaths in 6-16 year olds in the 1970-1980s occurred when there was a steep fall in post neonatal mortality rates and mortality rates in 1-5 year olds, which suggests that this reflects survival to a later age. This improved survival is due to multiple factors including earlier diagnosis and more intensive and effective treatment. It is possible that the figures may have been influenced by changes in coding and death certification and more accurate diagnosis. In the past, the recognition of deaths from cystic fibrosis may have been incomplete and mortality rates may have been underestimated. We cannot assess the influence on mortality from cystic fibrosis of factors which can alter the prevalence of the disease, such as prenatal diagnosis with therapeutic terminations, or of neonatal screening which became available during the period of our study.
Acute viral bronchiolitis is an important cause of hospital admissions and need for intensive care in infants. Deaths due to bronchiolitis in post-neonatal infants fell by over 92% between 1979 and 2000. During this time there was no change in ICD coding and no evidence of any change in the prevalence of bronchiolitis. It is probable that the reduction in the number of deaths reflects improvements in paediatric care and particularly paediatric intensive care.
In conclusion, we have observed a marked and progressive fall in deaths in childhood from respiratory disease. This decline has been more rapid than that seen for childhood deaths from all causes, so that today a smaller proportion of childhood deaths are the result of respiratory illness. The most significant decline was in deaths from pneumonia in the first year of life.
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